QQQ   436.76 (+0.00%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.71 (+5.74%)
AMD   175.62 (-0.51%)
BABA   76.50 (+0.71%)
T   16.74 (-0.36%)
F   12.23 (+0.74%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.63 (+0.85%)
DIS   108.40 (+0.61%)
AMC   4.52 (+1.80%)
PFE   27.40 (-1.30%)
PYPL   59.23 (+0.12%)
XOM   104.35 (+0.49%)
QQQ   436.76 (+0.00%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.71 (+5.74%)
AMD   175.62 (-0.51%)
BABA   76.50 (+0.71%)
T   16.74 (-0.36%)
F   12.23 (+0.74%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.63 (+0.85%)
DIS   108.40 (+0.61%)
AMC   4.52 (+1.80%)
PFE   27.40 (-1.30%)
PYPL   59.23 (+0.12%)
XOM   104.35 (+0.49%)
QQQ   436.76 (+0.00%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.71 (+5.74%)
AMD   175.62 (-0.51%)
BABA   76.50 (+0.71%)
T   16.74 (-0.36%)
F   12.23 (+0.74%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.63 (+0.85%)
DIS   108.40 (+0.61%)
AMC   4.52 (+1.80%)
PFE   27.40 (-1.30%)
PYPL   59.23 (+0.12%)
XOM   104.35 (+0.49%)
QQQ   436.76 (+0.00%)
AAPL   181.22 (-0.71%)
MSFT   410.30 (+-0.01%)
META   482.56 (-0.30%)
GOOGL   140.54 (-2.38%)
AMZN   175.34 (+0.20%)
TSLA   197.05 (+2.65%)
NVDA   789.11 (+0.12%)
NIO   5.71 (+5.74%)
AMD   175.62 (-0.51%)
BABA   76.50 (+0.71%)
T   16.74 (-0.36%)
F   12.23 (+0.74%)
MU   89.53 (+4.10%)
CGC   3.47 (+3.27%)
GE   154.63 (+0.85%)
DIS   108.40 (+0.61%)
AMC   4.52 (+1.80%)
PFE   27.40 (-1.30%)
PYPL   59.23 (+0.12%)
XOM   104.35 (+0.49%)
NASDAQ:ABUS

Arbutus Biopharma (ABUS) Stock Price, News & Analysis

$2.93
+0.01 (+0.34%)
(As of 09:44 AM ET)
Today's Range
$2.91
$2.95
50-Day Range
$2.19
$2.92
52-Week Range
$1.69
$3.14
Volume
135,244 shs
Average Volume
1.13 million shs
Market Capitalization
$491.36 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Arbutus Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
104.8% Upside
$6.00 Price Target
Short Interest
Healthy
3.65% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of Arbutus Biopharma in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.45) to ($0.39) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.23 out of 5 stars

Medical Sector

749th out of 935 stocks

Pharmaceutical Preparations Industry

347th out of 429 stocks


ABUS stock logo

About Arbutus Biopharma Stock (NASDAQ:ABUS)

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

ABUS Stock Price History

ABUS Stock News Headlines

ABUS Apr 2024 3.000 call
ABUS Sep 2024 3.000 call
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
Arbutus Biopharma (ABUS) to Release Earnings on Thursday
Blue Chips And Billionaires Quietly Investing In "The New Oil"
They're as essential to the tech and AI revolutions as oil was to the industrial revolution. Known as rare earth elements or REEs, these relatively unheard of commodities are essential to semiconductor chips, renewable energy, electric vehicles, and more.
Arbutus Biopharma Corporation (ABUS)
Arbutus Biopharma Corporation (ABUS)
Chardan Capital Reaffirms Their Buy Rating on Arbutus Biopharma (ABUS)
See More Headlines
Receive ABUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Arbutus Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2021
Today
2/26/2024
Next Earnings (Confirmed)
2/29/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ABUS
Employees
96
Year Founded
1992

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+105.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-69,460,000.00
Net Margins
-339.32%
Pretax Margin
-339.32%

Debt

Sales & Book Value

Annual Sales
$39.02 million
Book Value
$0.91 per share

Miscellaneous

Free Float
158,639,000
Market Cap
$489.68 million
Optionable
Optionable
Beta
2.04

Social Links

10 Best Stocks to Own in 2024 Cover

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

  • Mr. Michael J. McElhaugh (Age 49)
    Co-Founder, Interim President, CEO & Director
    Comp: $606.62k
  • Dr. Michael J. Sofia Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $628.43k
  • Mr. David C. Hastings CPA (Age 63)
    CFO & Chief Accounting Officer
    Comp: $647.1k
  • Ms. Lisa M. Caperelli
    Vice President of Investor Relations
  • Mr. J. Christopher Naftzger BA (Age 57)
    Esq., J.D., General Counsel & Chief Compliance Officer
  • Dr. Karen Sims M.D.
    Ph.D., Chief Medical Officer
  • Mr. R. Hector Mackay-Dunn B.A. (Age 73)
    J.D., L.L.B., Q.C., Secretary














ABUS Stock Analysis - Frequently Asked Questions

Should I buy or sell Arbutus Biopharma stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arbutus Biopharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ABUS shares.
View ABUS analyst ratings
or view top-rated stocks.

What is Arbutus Biopharma's stock price target for 2024?

3 Wall Street analysts have issued 1 year price objectives for Arbutus Biopharma's shares. Their ABUS share price targets range from $6.00 to $6.00. On average, they predict the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 104.8% from the stock's current price.
View analysts price targets for ABUS
or view top-rated stocks among Wall Street analysts.

How have ABUS shares performed in 2024?

Arbutus Biopharma's stock was trading at $2.50 at the start of the year. Since then, ABUS stock has increased by 17.2% and is now trading at $2.93.
View the best growth stocks for 2024 here
.

When is Arbutus Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 29th 2024.
View our ABUS earnings forecast
.

How can I listen to Arbutus Biopharma's earnings call?

Arbutus Biopharma will be holding an earnings conference call on Thursday, February 29th at 8:45 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Arbutus Biopharma's earnings last quarter?

Arbutus Biopharma Co. (NASDAQ:ABUS) posted its earnings results on Thursday, November, 4th. The biopharmaceutical company reported ($0.24) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.24). The biopharmaceutical company earned $3.34 million during the quarter, compared to analysts' expectations of $2.36 million. Arbutus Biopharma had a negative trailing twelve-month return on equity of 56.45% and a negative net margin of 339.32%. During the same quarter in the prior year, the firm posted ($0.27) EPS.

What ETFs hold Arbutus Biopharma's stock?

ETFs with the largest weight of Arbutus Biopharma (NASDAQ:ABUS) stock in their portfolio include Morningstar US Small Growth (MSGR) and iShares Genomics Immunology and Healthcare ETF (IDNA).Amplify Treatments, Testing and Advancements ETF (GERM).

What is Mark J. Murray's approval rating as Arbutus Biopharma's CEO?

6 employees have rated Arbutus Biopharma Chief Executive Officer Mark J. Murray on Glassdoor.com. Mark J. Murray has an approval rating of 22% among the company's employees. This puts Mark J. Murray in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Arbutus Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Arbutus Biopharma investors own include Ballard Power Systems (BLDP), Chiasma (CHMA), Bausch Health Companies (BHC), Heat Biologics (HTBX), Sorrento Therapeutics (SRNE), GW Pharmaceuticals (GWPH), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), TherapeuticsMD (TXMD) and Novavax (NVAX).

Who are Arbutus Biopharma's major shareholders?

Arbutus Biopharma's stock is owned by many different institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.57%), FourWorld Capital Management LLC (0.65%), BNP Paribas Financial Markets (0.17%), UBS Group AG (0.08%), Clear Harbor Asset Management LLC (0.08%) and Goldman Sachs Group Inc. (0.08%).
View institutional ownership trends
.

How do I buy shares of Arbutus Biopharma?

Shares of ABUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ABUS) was last updated on 2/26/2024 by MarketBeat.com Staff